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Abstract 
We have investigated the effect of the proteinase inhibitors 1,10-phenantroline (OP) and phenylmethylsulfonyl fluoride (PMSF) on 
steroidogenesis in rat adrenal cortex. Both PMSF and OP inhibited adrenocorticotropin (ACTH)- and 8-Br cAMP-induced stimulation of 
corticosterone synthesis. On the contrary, arachidonic acid-induced stimulation of corticosterone synthesis was only slightly inhibited by 
PMSF and unchanged by OP. Intra- and extracellular cAMP levels were determined by radioimmunoassay. While PMSF did not affect 
neither the intra- nor the extracellular cAMP levels, OP decreased the intra- and extracellular levels of unstimulated as well as 
ACTH-stimulated cells. The site of action of the proteinase inhibitors was also studied by recombination of mitochondria with the 
different subcellular fractions in vitro. Addition of PMSF abolished the stimulation achieved by in vitro activation of cytosol by cAMP 
and PKA. On the other hand, OP completely inhibited the activation of mitochondria. Our results provide vidence for the involvement of 
proteinases in ACTH-induced stimulation of steroidogenesis in adrenal cortex both prior to the release of arachidonic acid and at the level 
of cholesterol transport from the outer to the inner mitochondrial membrane. 
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1. Introduction 
In the mechanism of action of steroidogenic hormones 
it is widely accepted that the rate-limiting step in steroido- 
genesis is the transport of cholesterol from the outer to the 
inner mitochondrial membrane where it becomes the sub- 
strate of the cholesterol side cleavage enzyme complex 
[1-4]. 
The involvement of a protein kinase A-dependent phos- 
phorylation event is accepted as an intermediate step in the 
mechanism of action of adrenocorticotropin [5-7], luteiniz- 
ing hormone or chorionic gonadotropin [8-10]. 
Recently, it has also been demonstrated that activation 
of phospholipase A 2 with the concomitant release and 
metabolization of arachidonic acid is a necessary event in 
this cascade [11-16]. 
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A series of peptides and proteins have been postulated 
as intermediates in the mechanism of action of steroido- 
genic hormones. Among those, the sterol carrier protein 2 
(SCP 2), a 13-kDa protein synthesized as a 60-kDa precur- 
sor was described as a mediator in the transfer of choles- 
terol to the outer mitochondrial membrane [17-20]. A 
3.2-kDa peptide, steroidogenesis activator polypeptide 
(SAP) [21,22], was demonstrated to stimulate adrenal 
intramitochondrial cholesterol transfer in a synergistical 
way with GTP [20]. SAP is thought o be proteolytically 
derived from a 78-kDa minor heat shock protein, glucose 
regulatory protein 78 (GRP78). It has been suggested that 
SAP is produced by a protein kinase A-stimulated co- 
translational proteolysis [23]. 
Orme-Johnson and collaborators [24,25] and Stocco and 
collaborators [26,27] have described a group of mitochon- 
drial phosphoproteins whose appearance correlates with 
the stimulation of steroidogenesis. These proteins are syn- 
thesized first as 37-kDa precursors and processed to 32-kDa 
and finally to 30-kDa proteins presumably by the removal 
of signal and targeting sequences by specific proteases 
P. G. Mele et al. / Biochimica et Biophysica Acta 1310 (1996) 260-268 261 
found in the mitochondria [25,26]. These authors peculate 
that during the processing of these proteins the cholesterol 
may be transferred from the outer to the inner mitochon- 
drial membrane. Recently the cDNA that codes for the 
37-kDa and the 30-kDa proteins was cloned. It was also 
demonstrated that the expression of this cDNA could 
induce the steroid synthesis in the absence of hormonal 
stimulation [28]. Moreover, evidence has been presented 
showing that patients affected by congenital lipoid adrenal 
hyperplasia exhibit point mutations in the gene that codes 
for p37 protein [29]. 
The diazepam-binding inhibitor (DBI), the endogenous 
polypeptide ligand for tile peripheral or mitochondrial 
benzodiazepine r ceptor, and one of its processing prod- 
ucts, have also been suggested as intermediates in the 
stimulation of pregnenolone synthesis [30-33]. Recently it 
was shown that adrenocorticotropin increased the DBI 
processing, indicating that this increase in proteolytic ac- 
tivity elicited by adrenocorticotropin would mediate the 
acute action of the hormone [34]. 
We have demonstrated the presence of a soluble factor, 
that responds to the cAMP signal to induce steroid synthe- 
sis in adrenocortical tissue [35]. This factor, which was 
recently isolated, is a novel phosphoprotein with a molecu- 
lar mass of 43 kDa (p43). p43 stimulates mitochondrial 
steroidogenesis 12-fold and this effect could be blocked by 
inhibitors of phospholipase A 2, indicating a site of action 
for p43 prior to the release of arachidonic acid [36]. 
Recently, we have also shown an intrinsic proteolytic 
activity in p43 that was hormone-dependent [37]. In view 
of these data it seems reasonable to hypothesize the in- 
volvement of a proteolytic event on the mechanism of 
action of hormones in the stimulation of steroid synthesis. 
In this context, West et al. [38] have used proteinase 
inhibitors to demonstrate he requirement of proteolysis in 
luteinizing hormone-stimulated steroidogenesis in Leydig 
cells. 
This hypothesis has led us to study the effect of pro- 
teinase inhibitors on the ,stimulation of steroidogenesis in 
adrenal cells and the possible site of action of the prote- 
olytic activity in relation with the stimulation of mitochon- 
drial steroidogenesis. 
2. Materials and methods 
2.1. Materials 
Synthetic adrenocorticotropin, Synacthen [adrenocorti- 
cotropin-(1-24)-peptide] (ACTH, 1 fmol = 0.3 /zlU), 9- 
fluoro- 11/3,17,21-trihydroxy- 16 a methylpregna- 1,4-diene- 
3,20-dione (dexamethasone) and the inhibitors 2-methyl- 
1,2-di-3-pyridyl-l-propanone (M topyrone, 21-hydroxyl- 
ase inhibitor) and 1-(/3-guanidinoethyl)-3-(4-pyridyl)-indol 
sulfate (Ba 40.028, 11/3-, 18- and 19-hydroxylases in- 
hibitor) were a kind gift from Ciba Geigy (Basel, Switzer- 
land). 
Arachidonic acid, A-9673 (AA), 1,10-phenantroline 
(OP), 4-bromophenacyl bromide (BPB), adenosine 3',5'- 
cyclic monophosphate (cAMP), 8-Br cAMP, cAMP depen- 
dent-protein kinase (PKA), from rabbit muscle, 22(R)-OH 
cholesterol and bovine albumin, essentially fatty acid free, 
were purchased from Sigma Chemicals (St. Louis, MO, 
USA). 
Phenylmethylsulfonyl fluoride (PMSF) was purchased 
from Fluka Chemie (Switzerland). All other reagents were 
commercial products of the highest grade available. 
2.2. Animals 
Male Wistar rats (90 days old) were used throughout. 
Animals were supplied with dexamethasone (10 /zg/ml, 
ad libitum) in the drinking water for 16 h before sacrifice. 
Animals were sacrificed by decapitation and adrenals 
rapidly excised and kept on ice. 
2.3. Zona fasciculata cell preparation and treatment 
Obtention of zona fasciculata cells followed published 
procedures [39]. The cells were suspended in Krebs-Ringer 
bicarbonate solution (pH 7.4) [40] containing 10 mM 
glucose, 0.25% (w/v) bovine albumin and 0.1 mM 3-iso- 
butyl-l-methylxanthine (IBMX) (buffer A) and aliquoted 
in 1 mt-fractions containing 105 cells per tube. 
Proteinase inhibitors and/or the phospholipase A 2 in- 
hibitor were dissolved in ethanol and added to a final 
concentration of 0.1 mM for PMSF, 2 mM for 1,10- 
phenantroline and 10 /zM of 4-bromophenacyl bromide. 
Ethanol concentration never exceeded 1% in the assay but 
an equivalent amount was nevertheless added to control 
tubes. Preincubation was performed for 30 min in the 
conditions described above. Following preincubation 
adrenocorticotropin, 8-Br cAMP or 22(R)-OH cholesterol 
were added to the cell suspensions in 0.1 ml buffer A to a 
final concentration of 0.1 nM, 10 /zM and 5 /xM respec- 
tively. When used, arachidonic acid was added to the final 
concentrations indicated in figures in 0.1 ml buffer A from 
a fresh l0 mM stock dissolved in ethanol. 
After the appropriate additions, incubations proceeded 
for 2 h at 37°C in duplicate under O2/CO 2 (95:5, %) with 
shaking (100 cycles/rain), after which they were stopped 
by cooling the tubes on ice/water and the cells pelleted by 
centrifugation at 500 × g for 15 min. Supernatants were 
assayed for steroids and cAMP released into the medium 
(extracellular cAMP) as previously described [41]. Cortico- 
sterone, progesterone or pregnenolone were determined by 
radioimmunoassay [42]. 
2.4. Extracellular cAMP analysis 
A 0.7-ml sample of the supernatant was transferred to a 
glass tube, heated for 10 min in a boiling-water bath, 
cooled and centrifuged at 1700 × g for 20 rain; the super- 
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natant was kept frozen or used immediately for assay as 
indicated below. 
2.5. Total intracellular cAMP 
After incubations, cells corresponding to a half adrenal 
gland were used for intracellular cAMP measurement [41]. 
Cell pellets were washed once with buffer A, centrifuged 
at 500 X g for 15 min and resuspended in 0.7 ml of 20 
mM Tris-HC1 buffer (pH 7.4) containing 0.1 mM IBMX 
and 0.1 mM 2-mercaptoethanol. The suspensions were 
sonicated at 100 W for 15 s. The samples were transferred 
to glass tubes and heated in a boiling-water bath for 10 
min, transferred to small conical plastic tubes (10 mm X 35 
mm), centrifuged at 7300 × g for 15 min; the supernatant 
was kept frozen or used immediately for assay as indicated 
below. 
2.6. Radioimmunoassay of cAMP 
This was performed by the method of Steiner et al. [43] 
using a cAMP radioimmunoassay kit (NEK-133, New 
England Nuclear, Boston, MA, USA). An acetylation step 
was included as described by Harper and Brooker [44] to 
increase the sensitivity of the method to ~ 10 fmol. 
2.7. In vitro recombination assay 
In vitro recombination assay was performed as de- 
scribed elsewhere [45]. Briefly, adrenal zona fasciculata 
tissue from dexamethasone-treated rats was homogenized 
in 0.2 ml per adrenal gland of buffer B (270 mM mannitol, 
10 mM Tris-HC1 buffer, pH 7.4). The homogenate was 
centrifuged at 800 X g for 10 rain. The pellet containing 
cell debris and membranes was washed once with 0.5 ml 
buffer B and resuspended in 0.1 ml/adrenal gland of the 
same buffer. The mitochondrial fraction was obtained by 
centrifugation of the 800 X g supernatant a 9000 X g for 
20 min. The obtained pellet was rinsed with buffer B, then 
resuspended in 0.2 ml of fresh buffer B/adrenal gland. 
The 9000 × g supernatant (post-mitochondrial supernatant) 
was centrifuged at 105 000 X g for 60 rain to obtain the 
105000 X g pellet (microsomes and membranes pellet) 
and cytosol. The pellet was rinsed with buffer B and 
resuspended in 0.1 ml/adrenal gland of buffer B. In vivo 
activated fractions (activated post-mitochondrial super- 
natant and cytosol) were obtained from a group of dexa- 
methasone-treated animals that were injected subcuta- 
neously with 0.2 mg adrenocorticotropin/kg and sacrificed 
30 min later. 
The cytosol and the 105 000 X g pellet fraction or the 
post-mitochondrial supernatant corresponding to a half 
adrenal gland were recombined and preincubated with and 
without proteinase inhibitors (0.1 mM PMSF and/or 2 
mM 1,10-phenantroline) during l0 min at 37°C as indi- 
cated. Following preincubation, 0.35 ml buffer C (0.15 M 
Tris-HC1, pH 7.4/buffer B/0.3 M KCI/0.02 M MgC12, 
1:2:1:1, v /v )  containing 0.27 mM Metopyrone and 1.6 
mM Ba 40.028 were added to the incubation mix, together 
with 0.1 ml of mitochondrial fraction and buffer B until a 
0.8 ml volume was obtained. The mixture was incubated 
for another 10 rain at 37°C and stopped by cooling of the 
tubes on ice/water and addition of 2 ml cold methanol/2.5 
mM HC1 (1:1, v /v) / tube.  Steroids were extracted and 
determined by radioimmunoassay. The radioimmunoassay 
for pregnenolone seemed to be less specific than that for 
progesterone because a cross-reaction with lipophilic 
pregnenolone esters present in adrenal tissue could not be 
excluded. Therefore, the determination of progesterone 
was chosen as the main measurement of side-chain cleav- 
age. 
2.8. In vitro activation of cytosol 
The cytosol and the 800 X g and 105000 X g pellets 
corresponding to a half adrenal gland obtained from dexa- 
methasone-treated animals were preincubated in presence 
of 10 /~M ATP, 0.1 mM cAMP, 60 /xg/ml PKA in the 
presence of the proteinase inhibitors during 10 min at 
37°C. The mix was then completed by adding 0.35 ml 
buffer C containing the hydroxylation i hibitors, 0.1 ml of 
mitochondrial fraction and buffer B to a final volume of 
0.8 ml and incubation proceeded for another 10 min at 
37°C. 
The incubation was stopped as indicated before for the 
in vitro recombination assay. Steroids were extracted and 
Table 1 
Effect of proteinase and phospholipase A 2 inhibitors on the activation of corticosterone-synthesis in adrenocortical cells 
Preincubation Corticosterone (ng/adrenal) 
Vehicle ACTH 8-Br cAMP AA ACTH +AA 8-Br cAMP +AA 
Vehicle 2.9 + 0.5 30.7 ± 5.7 35.8 + 2.7 12.1 + 1.4 31.5 + 4.8 33.7 ± 3.0 
OP 2.8 + 0.7 4.4 ± 1.0 3.5 + 0.8 10.6 + 1.0 12.7 ± 0.6 12.9 ± 0.9 
PMSF 2.9 _+ 0.7 6.6 ± 0.7 3.7 + 0.3 7.1 ± 1.6 9.5 ± 1.1 8.4 ± 1.0 
BPB 2.4 + 0.9 7.3 ± 1.7 6.2 ± 0.5 11.7 + 1.7 11.6 ± 0.5 12.0 ± 1.1 
Adrenal zona fasciculata cells were preincubated (30 min, 37°C) with vehicle, 2 mM 1,10-phenantroline (OP), 0.1 mM PMSF or 10/xM 4-bromophenacyl 
bromide (BPB), and then incubated 120 min at 37°C in absence (vehicle) or presence of 0.1 nM adrenocorticotropin (ACTH), 10/xM 8-Br cAMP, 0.1 mM 
arachidonic acid (AA), 0.1 nM ACTH+0.1 mM AA, or 10 /zM 8-Br cAMP+0.1 mM AA as indicated in the table. Cells were removed and 
corticosterone production determined by radioimmunoassay in the incubation medium. Data represent mean 4- S.D. of four determinations. 
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progesterone production determined by radioimmunoassay 
[45]. 
2.9. Statistics 
Statistical analysis was by Student's t-test, and P < 0.05 
was used as the criterion for statistical significance. 
3. Results 
The experiments were designed to study the effect of 
proteinase and phospholipase A 2 inhibitors on the mecha- 
nism of activation of adrenocortical cells by adrenocorti- 
cotropin. 
Zona fasciculata cells, obtained as described in Section 
2, were incubated with proteinase and phospholipase A 2 
inhibitors prior to the stimulation with adrenocorticotropin, 
8-Br cAMP or arachidonic acid. 
Adrenocorticotropin, 8-Br cAMP and arachidonic acid 
produced a 10-, 10- and 4-fold stimulation of cortico- 
sterone synthesis respectively (Table 1). Addition of 
arachidonic acid together with adrenocorticotropin or 8-Br 
cAMP did not add to the amount of corticosterone pro- 
duced by adrenocorticotropin or 8-Br cAMP alone. 
Preincubation with the serine-proteinases inhibitor, 
PMSF and the metalloproteinases inhibitor, 1,10- 
phenantroline reduced in more than 80% the stimulation 
produced by adrenocorticotropin or 8-Br cAMP. On the 
contrary, 1,10-phenantroline had no effect on the increase 
in corticosterone synthesis; produced by arachidonic acid. 
Preincubation with PMSF !produced a slight decrease in the 
level of corticosterone r ached by arachidonic acid stimu- 
lation. When arachidonic acid was added together with 
adrenocorticotropin or 8-Br cAMP to cells that have been 
preincubated in the presence of 1,10-phenantroline, the 
levels of corticosterone were similar to that obtained with 
arachidonic acid alone. However, when preincubation was 
done in the presence of PMSF a slight decrease in cortico- 
sterone synthesis was observed when compared with the 
stimulation obtained by arachidonic acid alone. This sug- 
gests that PMSF may partially block the stimulation of 
corticosterone produced by arachidonic acid. 
Preincubation with 4-bromophenacyl bromide, an in- 
hibitor of phospholipase A 2, also reduced in more than 
80% the stimulation of corticosterone synthesis produced 
by adrenocorticotropin or 8-Br cAMP. On the other hand, 
this inhibitor was not able to block the corticosterone 
synthesis produced by arachidonic acid alone or in combi- 
nation with adrenocorticotropin or 8-Br cAMP (Table 1). 
Addition of arachidonic acid did not fully restore the 
effect of the hormones or 8-Br cAMP when the cells were 
preincubated with proteinase inhibitors. These results are 
in agreement with the failure of arachidonic acid to reach 
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Fig. 1. Stimulation ofcorticosterone synthesis inadrenocortical e ls by 
arachidonic acid. Adrenal zona fasciculata cells were incubated with 
increasing concentrations of arachidonic a id for 2 h at 37°C. Cortico- 
sterone production was determined in the incubation medium by radioim- 
munoassay. Data represent the mean ___ S.D. of six determinations. 
Arachidonic acid also increased pregnenolone synthesis 
by 2.5-fold as compared with the basal levels (control vs 
0.1 mM arachidonic acid: 12.2 4-2.0 vs 30.5 + 2.7 ng of 
pregnenolone/adrenal per2 h). This indicates that arachi- 
donic acid also stimulates the conversion of cholesterol 
into pregnenolone. 
Both the intra- and extracellular levels of cAMP were 
determined for the experiments with adrenocortical cells. 
Fig. 2 shows that preincubation of the cells in the presence 
of PMSF did not affect neither the intra- nor the extracel- 
lular cAMP levels. 1,10-phenantroline, however, decreased 
the intra- and extracellular levels both on unstimulated 
and on stimulated cells. 
The effect of the proteinase inhibitors on the ability of 
the subcellular fractions to stimulate progesterone produc- 
tion by isolated mitochondria was then tested using the in 
vitro recombination assay described in Section 2. Measure- 
ment in the presence of inhibitors of steroid hydroxylation 
in the assay allows the study of the different steps leading 
to the activation of the cholesterol side-chain cleavage as 
the reaction will proceed only to the conversion of choles- 
terol to pregnenolone and progesterone. Under those condi- 
tions, recombination of mitochondria with post-mitochon- 
drial fraction produced an approximately 4.5-fold stimula- 
tion of progesterone production when post-mitochondrial 
fractions from adrenocorticotropin-treated (ACTH) versus 
non-treated (control) animals are compared (11.3 4- 1.0 vs. 
2.4-4-0.8 ng/adrenal) (Fig. 3A). A similar result was 
obtained with cytosol from adrenocorticotropin-treated 
adrenals that stimulated control mitochondria in the pres- 
ence of the microsomal fraction by 3-fold (7.7 4- 0.7 vs. 
2.4 5- 0.2 ng/adrenal) (Fig. 3B). 
Values for mitochondrial progesterone production ob- 
tained by the stimulation of mitochondria using the in vitro 
recombination assay are comparable to those obtained 
from mitochondria isolated from adrenal glands of 
ACTH-treated animals (15.2 ng/adrenal). 
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When the post-mitochondrial fraction or the cytosol 
obtained from adrenocorticotropin-treated drenals were 
preincubated for 10 min at 37°C in the presence of PMSF, 
1,10-phenantroline or both, the inhibitors had no effect on 
the ability of those fractions to stimulate progesterone 
production by isolated mitochondria (Fig. 3A,B). 
Finally, the effect of proteinase inhibitors on the activa- 
tion of the cytosol was studied. For that purpose, soluble 
fraction from control adrenals was activated in vitro by the 
addition of cAMP and PKA, producing a 3-fold stimula- 
tion of progesterone production (Fig. 4). Addition of PMSF 
or a combination of both PMSF and 1,10-phenantroline 
abolished the stimulation of progesterone production 
elicited by cAMP and PKA (Fig. 4). 1,10-Phenantroline 
alone had no effect on progesterone production. 
In order to exclude a possible effect of proteinase 
inhibitors downstream of the cholesterol side-chain cleav- 
age, we studied the effect of PMSF and 1,10-phenantroline 
on the metabolism of 22(R)-OH cholesterol on adreno- 
cortical cells. Addition of 22(R)-OH cholesteroJ resulted in 
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Fig. 2. Effect of proteinase inhibitors on cAMP-production in adreno- 
cortical cells. Adrenal zona fasciculata cells were preincubated (30 min, 
37°C) with vehicle (open bars), 2 mM 1,10-phenantroline (hatched bars) 
or 0.1 mM PMSF (dotted bars), and further incubated for 120 min at 
37°C in the absence (control) or the presence of 0.1 nM adrenocorti- 
cotropin (ACTH) as indicated in the figure. Cells were centrifuged and 
supernatants a sayed for cAMP released to the medium (A). Cell pellets 
were washed and suspensions sonicated for intracellular cAMP measure- 
ment (B). cAMP was determined by radioimmunoassay. Data represent 
the mean_+ S.D. of four determinations. * P < 0.05, * * P < 0.001 versus 
respective control. 













Fig. 3. Effect of proteinase inhibitors on ACTH-induced progesterone 
production in a cell-free assay. Adrenal post-mitochondrial (A) or cytoso- 
lic (B) fractions obtained from dexamethasone-treated (control) or dexa- 
methasone and adrenocorticotropin-treated rats were preincubated with 
and without proteinase inhibitors, 2 mM 1,10-phenantroline (hatched 
bars), 0.1 mM PMSF (dotted bars) or a combination of both (horizontal 
bar), during 10 min at 37°C. The fractions were then recombined with 
control mitochondria (A) or control 800 X g and membrane fraction and 
mitochondria (B) as indicated in Section 2. Incubation by 10 min at 37°C 
was conducted and progesterone production determined by radioim- 





Fig. 4. Effect of proteinase inhibitors on in vitro-activated cytosols. 
Cytosol obtained from dexamethasone-treated (control) rats was activated 
in vitro by the addition of 0.1 mM cAMP and 60 /xg/ml PKA and 
preincubated with and without proteinase inhibitors, 2 mM 1,10- 
phenantroline (hatched bars), 0.1 mM PMSF (dotted bars) or a combina- 
tion of both (horizontal bars) during 10 min at 37°C. The fractions were 
then recombined with control mitochondria nd control 800X g and 
105000X g pellets and further incubated for 10 min at 37°C as indicated 
in Section 2. Progesterone production was determined by radioimmunoas- 
say. Data represents the mean 4- S.D. of four determinations. * * P < 0.001 
versus incubation without proteinase inhibitors. 
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Table 2 
Effect of PMSF and 1,10-phenantroline o  the conversion of 22(R)-OH cholesterol topregnenolone, progesterone and corticosterone 
265 
Treatment Steroids (ng/adrenal) 
Pregnenolone Progesterone Corticosterone 
Vehicle 12.2 + 2.0 2.6 + 0.5 3.2 + 0.8 
22(R)-OH cholesterol 140:1:18 31.3 + 2.3 35.4 + 2.8 
OP + 22(R)-OH cholesterol 239:1:30 12.5 _ 1.4 16.6 + 1.4 
PMSF + 22(R)-OH cholesterol 205 -4- 27 31.7 4- 2.4 41.2 + 3.5 
Adrenal zona fasciculata cells were preincubated (30 min, 37°C) with vehicle, 2 mM 1,10-phenantroline (OP) or 0.1 mM PMSF, and then incubated 120 
min at 37°C in absence (vehicle) or presence of 5 /zM 22(R)-OH cholesterol as indicated in the table. Cells were removed and steroids production 
determined by radioimmunoassay in the incubation medium. Data represent mean + S.D. of four determinations. 
cubation of the cells with PMSF had no effect on cortico- 
sterone synthesis. However, preincubation with 1,10- 
phenantroline reduced in approx. 50% the conversion of 
22(R)-OH cholesterol to corticosterone. 1,10-Phenantroline 
also prevented the conversion of pregnenolone into proges- 
terone by 40% but not the conversion of 22(R)-OH choles- 
terol to pregnenolone (Table 2). These findings are in 
contrast o that described in Figs. 3 and 4 where 1,10- 
phenantroline had no effisct on the activation of proges- 
terone synthesis. Since 1,10-phenantroline exhibited an 
inhibitory effect on cells preincubated for 30 min (Tables 1 
and 2) but not on mitochondria incubated for 10 min in its 
presence (Figs. 3 and 4), we investigated the time-depen- 
dence of 1,10-phenantroline action. 1,10-Phenantroline in-
hibited only the activation of progesterone synthesis when 
the recombined mitochondria were obtained from control 
adrenal glands that were incubated with 1,10-phenantroline 
for 30 min or when isolated mitochondria were incubated 
in the presence of 1,10-phenantroline for 30 rain (Table 3). 
However, this was a complete inhibition of mitochondrial 
Table 3 
Effect of 1,10-phenantroline o  the progesterone synthesis in mito- 
chondria from zona fasciculata 
Net progesterone 
synthesis (fold stimulation) 
Mitochondria I 2.19 + 0.10 
OP + Mitochondria I 1.18 ___ 0.02 
Mitochondria II 1.80 + 0.09 
OP + Mitochondria II 0.71 + 0.16 
Mitochondria were treated as follows: 
Mitochondria I: The mitochondrial fraction was obtained as described in
Section 2 and preincubated (30 min, 37°C) with or without 2 mM 
1,10-phenantroline (OP). Mitochondria II: Adrenal glands were incubated 
(30 min, 37°C) in Krebs-Ringer bicarbonate solution (pH 7.4) containing 
10 mM glucose and 0.5% (w/v) bovine albumin, in the absence or the 
presence of 2 mM 1,10-phenantroline. After this incubation, the mito- 
chondrial fraction was obtained as above. Both Mitochondria I and II 
were recombined with subcellular f actions as described inSection 2 and 
further incubated for 10 min at 37°C. Progesterone production was 
determined by radioimmunoassay. Results represent fold stimulation of 
progesterone synthesis + S.D. (four determinations) of mitochondria re- 
combined with activated cytosol as compared with mitochondria recom- 
bined with control cytosol (4.1 + 0.3 ng/adrenal). 
activation, suggesting that 1,10-phenantroline also blocked 
the conversion of cholesterol into pregnenolone. 
4. Discussion 
In this report we present evidence for the involvement 
of proteinases in ACTH-induced activation of steroidogen- 
esis in adrenal cortex. Our results are in agreement with 
previous experiments performed in Leydig cells [38]. 
PMSF and 1,10-phenantroline inhibited the hormonal 
stimulation of corticosterone synthesis in adrenocortical 
cells. The fact that both proteinase inhibitors could block 
the effect of 8-Br cAMP implies that the putative pro- 
teinases have their site of action after the production of 
cAMP. Accordingly, intra- or extracellular cAMP levels 
do not change in the experiments performed with PMSF. 
1,10-Phenantroline, on the contrary, decreased both the 
intra- and extracellular cAMP levels, implying an addi- 
tional different site of action for this inhibitor. 
Addition of arachidonic acid to fasciculata cells pro- 
duced a dose-dependent stimulation of steroid synthesis. 
Similar results were reported for glomerulosa [46] and 
Leydig cells [47]. It is known that adrenocorticotropin and 
luteinizing hormone in steroidogenic concentrations stimu- 
late arachidonic acid release in adrenal zona fasciculata 
[15] and Leydig cells [48] respectively. In agreement with 
previous observations [15,16], 4-bromophenacyl bromide, 
a phospholipase A 2 inhibitor, blocks the stimulation of 
steroid synthesis produced by adrenocorticotropin or 8-Br 
cAMP. Consequently, addition of arachidonic acid re- 
verted the inhibition of corticosterone production imposed 
by 4-bromophenacyl bromide to levels comparable to those 
obtained with arachidonic acid alone. Moreover, addition 
of exogenous arachidonic acid did not increase the cortico- 
sterone levels achieved by hormonal stimulation, indicat- 
ing that arachidonic acid acts in the same pathway that is 
used by the hormones. This is also reinforced by the 
finding that arachidonic acid stimulates pregnenolone syn- 
thesis. 
These results support the hypothesis that adrenocorti- 
cotropin acts through the phospholipase A 2 pathway to 
stimulate corticosterone production in adrenal cells. Acti- 
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vation of phospholipase A 2 and the subsequent release of 
arachidonic acid are, then, postulated as one of the final 
steps in the mechanism of action of adrenocorticotropin 
and luteinizing hormone. 
The failure of arachidonic acid to fully stimulate or to 
fully restore the effect of the hormones could probably be 
related to the uptake of arachidonic acid by the cells since 
increasing concentrations of arachidonic acid could not 
reach the level of stimulation that is obtained with the 
hormones. The same was observed in many cell systems 
where arachidonic acid has been demonstrated asan inter- 
mediate of cell response [I 2,49]. 
Addition of arachidonic acid also restored the cortico- 
sterone production blocked by proteinase inhibitors, revert- 
ing the synthesis to levels comparable to those obtained 
after incubation with arachidonic acid alone. This would 
indicate that proteinase inhibitors act prior to the release of 
arachidonic acid. PMSF, in addition, seems to partially 
decrease the effect of arachidonic acid, suggesting another 
proteolytic activity acting after the arachidonic acid re- 
lease. Since PMSF had no effect on the conversion of 
22(R)-OH cholesterol to corticosterone, it is expected to 
exert its action prior to the transport of cholesterol from 
the outer to the inner mitochondrial membrane. 
In order to determine the site of action of the pro- 
teinases involved in this mechanism, we analyzed the 
effect of the proteinase inhibitors on the ability of the 
isolated subcellular fractions to stimulate steroidogenesis 
using the in vitro recombination assay. It is apparent by 
analyzing the results of the recombination assay that both 
the in vivo activated cytosol as well as the cytosol acti- 
vated in vitro by addition of cAMP and PKA produced a
comparable stimulation of mitochondrial steroidogenesis. 
PMSF abolished the stimulation of steroidogenesis on 
control mitochondria only when the cytosol was activated 
in vitro by the addition of cAMP and PKA. This, along 
with the lack of effect of the inhibitor on 'in vivo stimu- 
lated' cytosols, indicates the requirement of a proteolytic 
event in the activation of steroidogenesis. Unexpectedly, 
no effect of 1,10-phenantroline could be registered along 
the pathway analyzed by the in vitro recombination assay. 
In view of our results, we postulate that one of the main 
events of proteolysis, that inhibited by PMSF, involved in 
adrenocorticotropin-stimulation of steroidogenesis, occurs 
after the production of cAMP and prior to the release of 
arachidonic acid. 
Since not PMSF nor 1,10-phenantroline affected mito- 
chondrial steroidogenesis when added to the in vitro 
recombination assay, one could expect no involvement of 
proteolysis at the mitochondrial level. However, in the 
case of 1,10-phenantroline, the lack of inhibition at the 
mitochondrial level is probably due to a lag period in its 
action. Mitochondria from glands incubated 30 min with 
1,10-phenantroline w re not able to respond in the cell-free 
assay. The same is true for mitochondria that are incubated 
in vitro with 1,10-phenantroline. This effect may be on the 
transport of cholesterol from the outer to the inner mito- 
chondrial membrane since 1,10-phenantroline cannot block 
the effect of 22(R)-OH cholesterol on pregnenolone pro- 
duction. 
These results are in agreement with those of Epstein 
and Orme-Johnson [25] and Stocco and Sodeman [26] that 
described the transformation f a 37-kDa precursor protein 
into a 30-kDa protein in the mitochondria in a hormone- 
dependent fashion, concurring with the cholesterol transfer 
from the outer to the inner mitochondrial membrane and 
indicating a proteolytic event occurring at the mitochon- 
drial level. Epstein and Orme-Johnson have shown that a 
15-min incubation with 1,10-phenantroline could not com- 
pletely block the cleavage of the precursor protein induced 
by cAMP in adrenal cells. However, Stocco and Sodeman 
showed that incubation of MA-10 cells with 1,10- 
phenantroline for 5 h resulted in the disappearance of p30 
with accumulation of the precursor forms correlating with 
a complete inhibition of progesterone synthesis. These 
results support he idea of a lag period for 1,10-phenantro- 
line action. 
1,10-Phenantroline also inhibited to some extent the 
conversion of pregnenolone into progesterone and cortico- 
sterone. However, in view of the mechanism of action of 
1,10-phenantroline, involving metal chelation, the results 
obtained in its presence must be analyzed with caution. 
Our results contrast, however, with those of Stocco et 
al. [26] in that unstimulated mitochondria re able to 
respond to cytosolic factors or to the addition of exoge- 
nous arachidonic acid. One possible explanation for this 
discrepancy could be that in the basal state there is enough 
p30 in the mitochondrial membrane, which in the presence 
of the arachidonic acid metabolites produced by hormonal 
stimulation, may provide sufficient cholesterol for the 
mitochondrial steroid synthesis. 
If p30 synthesis is an obligatory step in hormone-in- 
duced steroidogenesis and taking into consideration that 
phospholipase A 2 and proteinase inhibitors completely 
block the stimulation of steroid production, it is clear that 
proteolysis and phospholipase A 2 activation must be linked 
to p37 formation. 
However, these p37-p30 proteins may be necessary but 
not sufficient for full steroidogenesis. This hypothesis i in 
line with the finding that the maximal rate of progesterone 
production in cAMP-stimulated MA-10 cells is approx. 
200 ng of progesterone per mg of protein per hour, while 
p30-transfected cells produce progesterone ata rate of 166 
pg of progesterone per mg of protein per hour [28]. Since 
these differences cannot be accounted for by the difference 
in expression level of the 30 kDa protein in cAMP-stimu- 
lated cells as compared to transfected cells, one probable 
explanation is that the production of arachidonic acid, a 
cAMP-mediated event occurring during the acute response 
of steroidogenic tissues to hormone stimulation, is re- 
quired, together with the appearance of p30 in the mito- 
chondria, to obtain the maximal rate of steroid synthesis. 
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Other putative peptide intermediates involved in the 
stimulation of steroidogenesis were described like SCP 2, 
SAP and DBI [17-22,30--33]. If this is the case, all of 
them must be linked to proteolysis but also to arachidonic 
acid release, since inhibitors of proteinases or arachidonic 
acid release inhibit steroidogenesis a  well. 
We have recently demonstrated the presence of a phos- 
phoprotein, named p43, intermediate in the stimulation of 
arachidonic acid release and steroidogenesis [36], which 
exhibits an intrinsic proteolytic activity [37]. Additionally, 
cAMP and PKA acting on the cytosol can mimic the effect 
of adrenocorticotropin in vivo, measured as mitochondrial 
steroidogenesis activation. Since this effect is blocked by 
proteinase inhibitors, it can be suggested that one of the 
events linked with proteolysis may be the formation of 
bioactive phosphoprotein p43 from a cytosolic precursor 
by phosphorylation and proteolysis after adrenocorti- 
cotropin action. 
The isolation and characterization f the hormone-de- 
pendent proteinase involved in the stimulation of steroido- 
genesis acquires great relevance in view of the results 
presented here. 
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